140 active trials 80 recruiting 40 disease areas 13 changes in 30 days
7 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 5 with minor changes only.
Primary completion pushed from Oct 31, 2026 to Sep 30, 2027
Also in this update: Enrollment reopened; Enrollment increased: 10 → 30 participants
University of Kansas Medical CenterNot applicable NCT07223905 Registry history of NCT07223905 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
University of Kansas Medical CenterPhase 1 NCT07774039 Registry history of NCT07774039 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
University of Kansas Medical CenterPhase 2 NCT06428006 Registry history of NCT06428006 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 410 participants (planned 480)
University of Kansas Medical CenterNot applicable NCT05612971 Registry history of NCT05612971 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 16 participants (planned 21)
University of Kansas Medical CenterPhase 1/2 NCT06736717 Registry history of NCT06736717 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 2026 to Nov 2026
University of Kansas Medical CenterNot specified NCT07472088 Registry history of NCT07472088 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Enrolling by Invitation
University of Kansas Medical CenterNot applicable NCT05011942 Registry history of NCT05011942 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-08 | NCT07865013 AYA Cancer Transitions Program | Not Yet Recruiting | |
| 2026-09-25 | NCT07840482 FANS-Optimization of Irrigation and Suction Parameters in RIRS | Not Yet Recruiting |
| Early Phase 1 | 5 | |
| Phase 1 | 5 | |
| Phase 1/2 | 6 | |
| Phase 2 | 17 | |
| Phase 3 | 4 | |
| Phase 4 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06379724 | Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft | Burns | Recruiting | 2026-08-27 |
| NCT06478186 | Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes | Osteoarthritis, Knee | Recruiting | 2026-05-28 |
| Phase 3 | ||||
| NCT07174453 | Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of… | Solid Tumor Malignancies | Recruiting | 2026-07-01 |
| NCT05732272 | Improving Smoking Abstinence Outcomes in the African American Community Through Extended… | Smoking Cessation | Recruiting | 2026-02-23 |
| NCT05703672 | Switching to E-cigarettes in Smokers Not Interested in Quitting | Smoking Reduction | Recruiting | 2025-12-29 |
| NCT04789070 | Phase III Trial of Sirolimus in IBM | Inclusion Body Myositis | Active, Not Recruiting | 2026-01-14 |
| Phase 2 | ||||
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer | Breast Cancer | Recruiting | 2026-05-06 |
| NCT04530383 | Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function | Cystic Fibrosis-related Diabetes | Recruiting | 2026-04-15 |
| NCT05869812 | Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle… | Atrophy | Recruiting | 2026-03-02 |
| NCT06434571 | Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue… | Multiple Sclerosis | Recruiting | 2025-10-09 |
| NCT06364176 | Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic… | Cystic Fibrosis | Recruiting | 2025-05-02 |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective… | Bladder Cancer | Recruiting | 2025-02-20 |
| NCT04992780 | Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard… | Non Small Cell Lung Cancer Stage | Recruiting | 2023-12-07 |
| NCT06428006 | Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in… | Multiple Sclerosis | Active, Not Recruiting | 2026-10-08 |
| NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC | Breast Cancer | Not Yet Recruiting | 2026-08-04 |
| NCT07643584 | De-Escalation of Axillary Management in Advanced Nodal Disease | Breast Cancer | Not Yet Recruiting | 2026-06-11 |
| NCT05645380 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | Triple Negative Breast Cancer | Active, Not Recruiting | 2026-04-28 |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or… | Locally Advanced Cholangiocarcinoma | Active, Not Recruiting | 2026-02-24 |
| NCT04821141 | Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | Risk Reduction | Active, Not Recruiting | 2025-10-29 |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer… | Pancreatic Ductal Adenocarcinoma | Active, Not Recruiting | 2025-04-16 |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy… | Pancreas Cancer | Active, Not Recruiting | 2024-09-23 |
| NCT06129851 | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk… | Stage IIC Prostate Cancer AJCC v8 | Not Yet Recruiting | 2023-11-13 |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach… | Gastro Esophageal Junction Cancer | Active, Not Recruiting | 2023-05-19 |
| Phase 1/2 | ||||
| NCT04373057 | Prebiotic Galacto-oligosaccharide and Acute GVHD | Acute GVHD | Recruiting | 2026-04-22 |
| NCT04467723 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | NSCLC Stage IV | Recruiting | 2026-01-28 |
Obesity (12) · Breast Cancer (11) · Hypertension (7) · Bladder Cancer (5) · Alzheimer's Disease (4) · Diabetes (4) · Stroke (4) · Acute Lymphoblastic Leukemia (ALL) (3) · Cystic Fibrosis (3) · Multiple Sclerosis (3)